Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Dianthus Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $274.5 million for Q3 2025.

• On a quarterly basis, Cash from Financing Activities rose 92640.88% year-over-year to $274.5 million in Q3 2025; TTM through Sep 2025 was $314.9 million, a 49.19% increase from a year earlier, with the FY2024 full-year figure at $255.6 million, up 91.37% from the prior year.
• Cash from Financing Activities climbed to $274.5 million in Q3 2025 per DNTH's latest filing, from $568000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $274.5 million in Q3 2025 and bottomed at -$4.9 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is $418000.0 (2021), against an average of $56.7 million.
• Across the five-year window, Cash from Financing Activities plunged 99.94% in 2022 and jumped 92640.88% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $124000.0 in 2021, then jumped by 77825.0% to $96.6 million in 2022, then sank by 105.03% to -$4.9 million in 2023, then soared by 915.54% to $39.7 million in 2024, then jumped by 591.89% to $274.5 million in 2025.
• Per Business Quant, the three latest DNTH Cash from Financing Activities figures stand at $274.5 million (Q3 2025), $568000.0 (Q2 2025), and $161000.0 (Q1 2025).